SanBio reports foreign exchange loss, deferred tax liabilities, nets ¥14.3 bn from share issue

SanBio Co., Ltd. recorded a ¥395 million foreign exchange loss as a non-operating expense for the nine months ended October 31, 2025. This was primarily due to currency fluctuations impacting foreign currency-denominated loans and related receivables to a consolidated subsidiary. Concurrently, a deferred income tax of negative ¥446 million was recognized due to deferred tax liabilities associated with these instruments.

These events contributed to an operating loss of ¥2,673 million, an ordinary loss of ¥3,159 million, and a net loss attributable to owners of parent of ¥2,713 million for the period. Total net assets decreased by ¥1,270 million to ¥492 million, while total assets decreased to ¥2,406 million. The company's full-year earnings forecast remains unchanged.

In a subsequent event, SanBio resolved on November 6, 2025, to issue 6,000,000 shares of common stock through an international offering, completing payment on November 21, 2025. This generated ¥14,265,840,000 in proceeds, increasing capital stock and capital reserves by ¥7,132,920,000 each. The funds are earmarked for establishing AKUUGO promotion in Japan, and clinical trials for SB623 traumatic brain injury in the US and ischemic stroke in Japan.